Menumenu
  • Home
  • Drug utilization study Publications

Drug utilization study Publications

Drug utilization study Publications

  • Increased use of antimicrobial agents and hospital admission for infections in patients with primary adrenal insufficiency: a cohort study.Abstract

    BACKGROUND: Previous studies have suggested that infections are an important cause of death in patients with Addison’s disease, but epidemiological studies on the frequency of infections in this population are lacking. OBJECTIVE: To assess and compre the incidence risk of infections in patients with primary adrenal insufficiency with controls

    Smans LC, Souverein PC, Leufkens HG, Hoepelman AI, Zelissen PM. Eur J Endocrinol. 2013 Apr; 168 (4): 609-14.
  • Population-based analysis of non-steroidal anti-inflammatory drug use among children in four European countries in the SOS project: what size of data platforms and which study designs do we need to assess safety issues?.Abstract

    BACKGROUND: Data on utilization patterns and safety of non-steroidal anti-inflammatory drugs (NSAIDs) in children are scarce. The purpose of this study was to investigate the utilization of NSAIDs among children in four European countries as part othe Safety Of non-Steroidal anti-inflammatory drugs (SOS) project

    Valkhoff VE, Schade R, tJong GW, Romio S, Schuemie MJ, Arfe A, Garbe E, Herings R, Lucchi S, Picelli G, Schink T, Straatman H, Villa M, Kuipers EJ, Sturkenboom MC, investigatorsofTheSafetyofNon-steroidalAnti-inflammatoryDrugs project. BMC Pediatr. 2013 13 192.
  • Use and costs of oral anticancer agents in the Netherlands in the period 2000-2008.Abstract

    PURPOSE: In recent years, the number of oral anticancer agents has increased substantially. Although these agents have quickly been incorporated in the treatment of a variety of malignancies, data on their incidence, prevalence and costs are lackin. The objective of the present study was to obtain insight into the use and the costs of oral anticancer agents (with Anatomical Therapeutic Chemical classification system (World Health Organisation) code L01) in the Netherlands between 2000 and 2008

    Timmers L, Beckeringh JJ, van Herk-Sukel MP, Boven E, Hugtenburg JG. Pharmacoepidemiol Drug Saf. 2012 Oct; 21 (10): 1036-44.
  • Prescribing of rosiglitazone and pioglitazone following safety signals: analysis of trends in dispensing patterns in the Netherlands from 1998 to 2008.Abstract

    BACKGROUND: Relevant safety signals in the EU are regularly communicated in so-called ‘Direct Healthcare Professional Communications’ (DHPCs) or European Medicines Agency (EMA) press releases. Trends of a decrease in the use of rosiglitazone followng regulatory safety warnings have been described in the US

    Ruiter R, Visser LE, van Herk-Sukel MP, Geelhoed-Duijvestijn PH, de Bie S, Straus SM, Mol PG, Romio SA, Herings RM, Stricker BH. Drug Saf. 2012 Jun 1; 35 (6): 471-80.
  • Differences in lithium use patterns in the Netherlands: comparing middle-aged and older patients in a database study.Abstract

    BACKGROUND: Age-dependent changes in lithium pharmacokinetic and pharmacodynamic properties can influence lithium use in an aging population, especially as newer treatment options are available. OBJECTIVE: We compared lithium use patterns between mddle-aged and elderly outpatients in the Netherlands

    van Melick EJ, Wilting I, Souverein PC, Egberts TC. Am J Geriatr Pharmacother. 2012 Jun; 10 (3): 193-200.
  • Impact of orlistat initiation on cardiovascular treatment use: a 6-year population-based cohort study.Abstract

    BACKGROUND: Trials of weight-loss drugs indicate some benefits on lipids, blood glucose, or blood pressure levels. Since obesity is associated with increased cardiovascular (CV) medication use and pharmaceutical costs, weight-loss drug use could beeficially impact CV medication use. OBJECTIVE: We examined the temporal associations between CV drugs use 3 years before and after the initiation of orlistat, a weight-loss drug

    Czernichow S, Knol MJ, Fezeu L, Grobbee DE. Eur J Prev Cardiol. 2012 Jun; 19 (3): 484-9.
  • Venous thromboembolism prophylaxis after total knee or hip replacement: treatment pattern and outcomes.Abstract

    PURPOSE: To determine the thromboprophylactic treatment pattern and occurrence of venous thromboembolism (VTE), major bleeding, and wound infections in patients undergoing total knee replacement (TKR) or total hip replacement (THR). METHODS: From te PHARMO database, all patients >/= 18 years hospitalized for TKR or THR between January 2003 and September 2008 were selected

    Penning-van Beest FJ, Overbeek JA, Meijer WM, Woodruff K, Jackson J, van der Vis H, van der Linden P, Herings RM. Pharmacoepidemiol Drug Saf. 2011 Sep; 20 (9): 972-8.
  • Time-trends in treatment and cardiovascular events in patients with heart failure: a pharmacosurveillance study.Abstract

    AIMS: We assessed, in patients with a first hospitalization for heart failure (HF), the temporal relationship of the incidence of cardiovascular events, all-cause mortality, and cardiovascular drug treatment. METHODS AND RESULTS: Data were obtainedfrom the PHARMO Record Linkage System, a population-based registry of pharmacy records linked with hospital discharge records in The Netherlands

    de Peuter OR, Lip GY, Souverein PC, Klungel OH, de Boer A, Buller HR, Kamphuisen PW. Eur J Heart Fail. 2011 May; 13 (5): 489-95.
  • Pharmacologic treatment of attention-deficit/hyperactivity disorder in children: incidence, prevalence, and treatment patterns in the Netherlands.Abstract

    BACKGROUND: The prevalence of attention-deficit/hyperactivity disorder (ADHD) and the associated use of stimulant medications may have increased in the Netherlands in recent years, but there is a lack of data to confirm this trend. This retrospectie analysis examined the incidence, prevalence, and treatment pattern of ADHD among children from a large sample representation of the general population of the Netherlands and represents the first such analysis in a large cohort of European children

    Hodgkins P, Sasane R, Meijer WM. Clin Ther. 2011 Feb; 33 (2): 188-203.
  • Three-year dispensing patterns with long-acting inhaled drugs in COPD: a database analysis.Abstract

    BACKGROUND: Long-acting muscarinic antagonists (LAMA), long-acting beta2-agonists (LABA) and fixed dose combinations (FDC) of inhaled corticosteroids (ICS) and LABA are used as inhaled maintenance therapies for COPD. OBJECTIVE: To estimate persistece rates from dispensing patterns of long-acting inhaled drugs for COPD

    Penning-van Beest F, van Herk-Sukel M, Gale R, Lammers JW, Herings R. Respir Med. 2011 Feb; 105 (2): 259-65.